TherapeuticsMD (TXMD) Profit After Tax Growth (1y) (2011 - 2026)
TherapeuticsMD (TXMD) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 67.73% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.33% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1,682.88% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | TherapeuticsMD | 280,418.39 | -8.14 Mn | - | 114.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 114.55% |
| Dec 31, 2025 | -536.36% |
| Sep 30, 2025 | 108.82% |
| Jun 30, 2025 | 150.55% |
| Mar 31, 2025 | 11.04% |
| Dec 31, 2024 | 113.70% |
| Sep 30, 2024 | 83.21% |
| Jun 30, 2024 | 54.85% |
| Mar 31, 2024 | 79.63% |
| Dec 31, 2023 | -100.55% |
| Sep 30, 2023 | 76.91% |
| Jun 30, 2023 | -102.15% |
| Mar 31, 2023 | 92.65% |
| Dec 31, 2022 | 470.99% |
| Sep 30, 2022 | 69.15% |
| Jun 30, 2022 | 363.25% |
| Mar 31, 2022 | -24.47% |
| Dec 31, 2021 | -2.07% |
| Sep 30, 2021 | -45.41% |
| Jun 30, 2021 | 17.94% |